Results · Apr-Jun 2026 · filed 11 Aug 2026
Bafna Pharmaceuticals Q1 FY27 results
Sales fell 23% to ₹26.6 crore from ₹34.6 crore in Apr-Jun 2025.
Operating profit fell 83% to ₹0.88 crore, an operating margin of 3.3% (down 11.3 points from a year ago).
Net profit fell 98% to ₹0.08 crore from ₹3.4 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −37%, net profit −97%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 26.6 | 34.6 | −23% |
| Operating profit (EBITDA) | 0.9 | 5.1 | −83% |
| Operating margin | 3.3% | 14.6% | −11.3 pts |
| Net profit | 0.1 | 3.4 | −98% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 14 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 13 Aug 2026Book Closure For 31St Annual General Meeting
- 13 Aug 2026Shareholder Meeting - 31St AGM On September 11, 2026
- 11 Aug 2026Unaudited Financial Results For The Quarter Ended June 30, 2026
- 11 Aug 2026Board Meeting Outcome for The Board Meeting Held On 11/08/2026
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.